➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
McKesson
Harvard Business School
AstraZeneca

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

Litigation Details for Shire Orphan Therapies LLC v. Fresenius Kabi USA, LLC (D. Del. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Shire Orphan Therapies LLC v. Fresenius Kabi USA, LLC (D. Del. 2015)

Docket   Start Trial Date Filed 2015-11-29
Court District Court, D. Delaware Date Terminated 2018-06-05
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Patents 10,030,059; 10,036,037; 10,036,054; 10,041,044; 10,046,056; 10,046,058; 10,047,033; 8,039,010; 8,048,017; 9,005,056; 9,020,056; 9,024,034; 9,040,034; 9,040,039; 9,056,052; 9,056,057
Link to Docket External link to docket
Small Molecule Drugs cited in Shire Orphan Therapies LLC v. Fresenius Kabi USA, LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Shire Orphan Therapies LLC v. Fresenius Kabi USA, LLC

Details for Shire Orphan Therapies LLC v. Fresenius Kabi USA, LLC (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2018-02-28 107 addressed was, is Claim 14 of the 10:47:33 6 '333 patent an obvious variant of Claim 1 of… another patent that claims the same discovery as the '333 09:07:39 13 patent, the same… 14 contained in this patent is contained in the '7,803 patent 09:07:53 15 that Shire…That patent already expired. Shire is not 09:08:01 17 entitled to the second patent but…7,803 patent, and in fact the application 09:08:20 22 that resulted in the '333 patent was External link to document
2018-02-28 108 Did I read that correctly? 09:05:56 12 A. You did. 09:05:58 13…exhibit Knolle 5, the '333 patent, which 10:13:30 9 is the patent in suit in this case. …participate when those patents were being 11:00:55 23 prosecuted at the Patent Office? 11:00:57…How many patents issued from the 11 applications in 11:19:11 5 the '333 patent prosecution…19:14 6 A. Only one patent issued, the '333 patent. 11:19:17 7 Q. And External link to document
2018-02-28 109 you look at 3.31, if you go to these 10:30:59 17 patents, position eight here is called Z. … the '993 patent, 11:55:33 20 the '613 patent and the '963 patent. Right… '333 patent is not invalid for 09:13:42 8 obviousness-type double patenting over Claim…09:13:53 11 patent is not invalid for obviousness-type double patenting 09:13:57 12 …the '333 patent, the 09:14:13 16 meaning of Claim 14 of the '333 patent, the meaning External link to document
2018-02-28 110 Hans-George Alpermann. 10:30:59 11 Q. Who is the '7,803 patent assigned to? 10:31:05…you telling the Patent Office here? 10:21:37 19 A. We are telling the Patent Office that we…the U.S. patent 5,597,803. 10:29:36 15 Q. Did you prosecute the '803 patent? 10:29…same for the '7,803 patent and 10:30:41 7 the '333 patent? 10:30:44 8 …#39;333 patent 10:31:14 15 before the application was filed for the '7,803 patent? 10:31 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
McKinsey
Harvard Business School
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.